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Abstract 
Vanadium (V) was rediscovered for biology as a “muscle 
inhibitor factor” when it was found in commercial ATP 
prepared from equine muscle almost thirty years ago. Since 
then it has been used as a molecular probe of the mechanisms 
of several enzyme reactions involving hydrolysis of phosphate 
ester bonds. Besides acting as a phosphate analogue, 
vanadate has also the potential to exhibit biological activities 
through oligomeric vanadate species. Among the vanadate 
oligomers, decavanadate is one of the most potent inhibitors 
and has revealed an excellent kinetic and spectroscopic 
probe. This is particularly relevant for myosin, the major 
muscle ATPase which along with actin is able to convert the 
chemical energy of ATP hydrolysis into mechanical work. 
Apparently, vanadate is able to populate different 
conformational states of the myosin ATPase cycle depending 
on its oligomerization state. While monomeric vanadate 
(VO43-) mimics the transition state for the γ-phosphate 
hydrolysis blocking myosin in a pre-power stroke state, 
decameric vanadate (V10O286-) induces the formation of the 
intermediate myosin·MgATP·V10 complex blocking the 
actomyosin cycle in a pre-hydrolysis state. These recent 
findings, that are now reviewed, point out to the importance 
of taking into account vanadate species variety in studies 
describing the interaction of vanadate with biological 
systems and incite the use of decavanadate as a biochemical 
tool to the elucidation of muscle contraction regulation. 
. 
 
*Correspondence/Reprint request: Teresa Tiago, Faculdade de Ciências 
e Tecnologia, Universidade do Algarve, Campus de Gambelas, 8005-139 
Faro, Portugal.                                                          e-mail: ttiago@ualg.pt 
 
 
1. INTRODUCTION 
 
Skeletal muscle cells and vanadium are strongly connected to each other, since 
Josephson and Cantley [1] identified an impurity in commercial ATP prepared from 
equine muscle as orthovanadate (V), a potent inhibitor of the sodium pump. Although 
thirty years have passed since the discovery of this naturally occurring inhibitor, the 
function of this element in muscle cells is still unidentified. This is not surprising if one 
consider the exceptional complex chemistry of vanadium in solution especially in what 
concerns the propensity of vanadium species to condense at higher concentrations or 
acidic pH’s, forming vanadate oligomers, or to interact with countless compounds of 
biological interest [2,3].  
Numerous researchers working in different areas ranging from life sciences to 
chemical engineering, using vanadate in their studies, have to deal with the tendency of 
vanadate species to oligomerize. At neutral pH and through the range of concentrations 
most frequently employed in biochemical studies, the predominant vanadate species are 
the monomer (H2VO4-), dimer (H3V2O7-) and tetramer (V4O124-) [4,5]. Given the rapid 
exchange rates between the labile oligovanadates it is not possible to isolate a specific 
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anion and consequently an equilibrium mixture must be examined [6], which may 
complicate studies aimed to determine the effect of a specific anion. At alkaline pH, the 
monomeric species is more prevalent and therefore researchers frequently prepare 
“activated” solutions of monomeric vanadate by adjusting the pH of a stock solution of 
sodium orthovanadate above 10 and heating near 100ºC until the solution is colourless 
[7]. However, for studies at physiological pH these highly basic vanadate solutions 
require neutralisation with HCl raising the potential for serious contamination with 
substantial amounts of decameric species (V10O286-). Since methods for preparing 
vanadate solutions are not frequently cited it is uncertain if studies using vanadate 
solutions also include meta- or decameric species as contaminants. 
Our laboratory has dedicated over the last 20 years many efforts to learn more 
about the contribution of oligomeric vanadate species to vanadium effects on muscle 
contraction/relaxation, namely on sarcoplasmic reticulum Ca2+-ATPase transmembrane 
transport system and on myosin and actomyosin ATPase activities. Among the vanadate 
oligomers, decameric species has revealed the most interesting in biochemical terms. 
Besides having high potency in a number of systems, the lower lability of this large 
polyoxoanion allows it to be use as an excellent kinetic and spectroscopic probe. The 
effects of decavanadate on Ca-pump have been recognized for some time and reviewed 
elsewhere [chapter 7] and therefore are out of the scope of this review. The focal point 
of this chapter concerns the use of decameric vanadate as a structural-functional tool for 
further understanding the mechanism of actomyosin action based on studies combining 
kinetic, spectroscopic and molecular modelling methodologies. In the next sections our 
recent findings on the structural/functional interaction of vanadate oligomers with the 
actomyosin system are summarized and the decameric vanadate binding mode and 
inhibition mechanism compared to the well established monomeric vanadate reactivity 
towards myosin.  
 
2. MYOSIN AND ACTOMYOSIN ATPase ACTIVITY INHIBITION BY 
VANADATE 
 
Most of the biological importance of vanadium is associated with the 
pentavalent form (vanadate) due to the similarities between the phosphate and vanadate 
chemistries in solution. The enzyme regulatory properties of vanadate depend on its 
esterification with phosphate or hydroxyl groups of biological molecules [8]. Thus, 
enzymes involved in phosphohydrolase and phosphotransferase reactions can accept 
vanadium as an analogue of orthophosphate, forming an inhibitory complex between 
the enzyme and vanadate. This is particularly relevant for myosin, the major ATPase of 
muscle which along with actin is able to convert the chemical energy of ATP hydrolysis 
into mechanical work during the process of muscle contraction [9]. The head segment of 
myosin, called subfragment-1 (S1), contains the binding sites for ATP and actin, and is 
responsible for the ATPase activity [10]. During the contractile cycle, binding of ATP 
reduces the affinity of myosin for actin, and the subsequent hydrolysis of ATP results in 
a ternary complex between myosin, ADP and inorganic phosphate (Pi). The rate-
limiting step of the ATP hydrolysis is the release of Pi from myosin, which is 
accelerated by the rebinding of actin (Fig. 1). Goodno [11] has originally demonstrated 
that, in the absence of actin, vanadate inhibits myosin ATPase activity by forming a 
very stable complex with MgADP that mimics either the transition state of hydrolysis or 
the ADP·Pi intermediate state. This inactive complex has a stoichiometry of one ADP 
and one vanadate (Vi) per myosin active site and a half-life of approximately 3 days at 
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25 ºC. This complex arrests the contractile cycle at a critical point and therefore has 
provided an opportunity to study this important state.  
The behaviour of the myosin·MgADP·Vi complex was also studied in the 
presence of actin [12,13]. However, just as actin increases the rate of release of Pi from 
the myosin·MgADP·Pi complex, it also manifestly increases (by 105) the rate of Vi 
dissociation from the myosin·MgADP·Vi complex [14]. Therefore, there is a 
considerably difference in the ability of vanadate to inhibit the myosin and the 
actomyosin ATPase activity. While in the absence of actin Vi inhibits myosin ATPase 
activity in the submicromolar concentration range, in the presence of actin much higher 
concentrations (> 900 microM) are needed [13]. Clearly, the need for such high 
concentrations strongly suggested that this effect could be due to oligomeric vanadate 
species that are favoured at higher vanadate concentrations and likely to occur through a 
different mechanism. This possibility was further investigated starting by clarifying 
which vanadate oligomers interact more potently with myosin and how is this 
interaction modulated by the myosin natural ligands such as ATP and actin.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Relevant steps of the actomyosin ATP hydrolysis cycle schematically represented (grey) as 
perturbed by orthovanadate binding (black). M, myosin; Vi, orthovanadate. The dominant process of ATP 
hydrolysis observed in vitro is indicated by the filled arrows. Formation of the M·ADP·Vi complex is fast 
and reversible but isomerization is essentially irreversible forming a stable ternary complex M†·ADP·Vi 
as described by Goodno [11].   
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3. VANADATE OLIGOMERS INTERACTION WITH MYOSIN: 51V-NMR 
SPECTROSCOPY ANALYSIS 
 
Vanadate compounds are excellent probes of their surroundings due to the rapid 
quadrupolar relaxation in solution, large magnetic moment and high natural abundance 
(99.76%) of the 51V nucleus. Resolvable 51V NMR spectra can be obtained in a matter 
of minutes and the chemical shifts can be use to monitor changes in the vanadium (V) 
coordination sphere as they are very sensitive to changes in the electronic nature of the 
vanadium atom [15-17]. The distribution of the different vanadate oligomers present in 
the 51V NMR spectra can reflect changes in ionic strength, concentration, pH and 
temperature [18-20]. Therefore, 51V NMR spectroscopy besides being a convenient 
method to monitor the speciation of oxovanadates has proved to be highly informative 
in biological systems as experiments can be designed to evaluate specific interactions of 
the different vanadate oligomers with compounds of the biological system [21-26].  
The 51V NMR approach was applied to myosin and subfragment-1 and 
demonstrated that, in the absence of ATP, of the various forms of vanadate in solution 
essentially only the tetrameric form binds to the protein [27,28]. Ringel and 
collaborators showed soon after that the presence of myosin or S1 in a metavanadate 
solution produced a significant broadening of the signal of each form of vanadate (di-, 
tetra- and hexa-vanadates) being interpreted as indicative that all of them bind to the 
protein [29]. Nevertheless, since these oxovanadates are in rapid equilibrium [5], the 
broadening of the signals is dictated by the total population of free exchanging 
oxovanadates and may imply that only one of the labile species is binding to the protein. 
In subsequent studies with meta- and decavanadate solutions it was obtained a relative 
order of line broadening upon myosin addition of V10 > V4 > V1 where no changes were 
observed for monomeric vanadate [30,31].  
Decavanadate, contrarily to the labile oxovanadates (V1, V2, V4 and V5) has an 
equilibration time with the other species sufficiently long that the disappearance of the 
NMR signals can be attributed to protein binding [5,6]. Taking advantage of this lower 
lability, the binding mode of decavanadate to myosin was further explore by analyzing 
the competition with the other oligomers for the binding sites on myosin under the 
influence of natural ligands, such as actin and ATP [32]. For that purpose changes in the 
51V NMR signals were monitored upon protein addition to a metavanadate solution (2 
mM) containing approximately 766 µM V1, 146 µM V2, and 236 µM V4 (Fig. 2A) and 
to a mixed solution containing 2 mM-metavanadate and 5 mM-decavanadate 
(polyvanadate solution), containing approximately 908 µM V1, 300 µM V2, 219 µM V4 
and 461 µM V10 (Fig. 2B). These studies pointed out to a competition between 
decameric and tetrameric vanadate species for the same myosin binding sites. The most 
reasonable explanation for these results is that V10 and V4, as polyanionic species, bind 
to a cationic portion of myosin S1 with electrostatic forces involved as it was confirmed 
by the results, namely: (i) V10 has a greater affinity for the myosin binding sites than V4, 
in the same way that, V4 has greater affinity than the lower vanadate oligomers; (ii) V10 
interaction is favored for higher ionic strengths (not showed). In addition, these studies 
confirmed that the interaction of the oligomers with myosin S1 is modulated by the 
enzyme natural ligands, i.e., is affected in the presence of the nucleotide and appears to 
be favored in the presence of F-actin filament.  
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Figure 2. 51V NMR spectra of metavanadate (2.0 mM) and polyvanadate (2.0 nominal metavanadate + 
5.0 mM nominal decavanadate) solutions in the absence and presence of 30 µM S1 and 2 mM ATP. The 
spectra were collected in a medium containing 25 mM KCl, 25 mM Hepes (pH 7.0) at 25 ºC. V1, V2 and 
V4 are referring to monomeric, dimeric and cyclic tetrameric forms of vanadate, respectively. V10A, V10B, 
and V10C correspond to the three chemical environmental different vanadate atoms in the decameric 
vanadate structure.   
 
4. COMPOSITION OF DECAVANADATE SOLUTIONS AND STABILITY OF 
DECAMERIC SPECIES  
 
Preparation of vanadate solutions containing decameric species have been 
developed to study the interaction and/or effects promoted by these species in the 
biological systems [21,33-39]. Nevertheless, the denominated “decavanadate” solutions 
containing presumably only the decamer are often contaminated with other species. In 
fact, the composition of the decavanadate solutions will depend on the time after which 
the decavanadate stock solution is diluted in the reaction medium and on the conditions 
of the medium itself (pH, temperature and ionic strength). As appraised by 51V NMR 
spectroscopy, a decavanadate stock solution of 100 mM total vanadium concentration at 
pH 4.0 will contain 10 mM decameric vanadate species and, therefore, with no 
contamination of any other species. Upon dilution into the reaction medium, at 
physiological pH and room temperature, the decavanadate solution will contain besides 
the decamer, a contamination of about 5-10% of other vanadate species [40]. This 
percentage is independent of the total vanadate concentration for a fixed time 
(approximately 30 min) and therefore V10 shows a linear correlation with the increase in 
total vanadate concentration (Fig. 3). Since V10 is in equilibrium with V1, the 
appearance of other vanadate oligomers is dependent on V1 concentration, i.e., above 
200 µM V1 starts to oligomerize giving rise to di- and tetrameric vanadate species. 
Therefore, when a stock solution of decavanadate is diluted into the reaction medium, 
for instance, at a concentration of 1 mM (total vanadium), 51V-NMR spectra shows an 
additional signal from V1 (∼100 µM), that is about 1:1 stoichiometry of decameric and 
monomeric vanadate species. 
Although NMR spectroscopy is an essential technique for the analysis of 
vanadate oligomers composition, the poor sensitivity as well as the long time it takes to 
acquire a spectra, unable its use to follow the dissociation kinetics of decameric species. 
However, the disappearance of the decamer can be easily followed by UV/Vis 
spectroscopy. Lacking d-electrons, vanadium(V) shows no transitions in the visible 
 7 
                                        
                                        
                                        
                                        
                                        
                                        
-2 0 2 4 6 8 10 12 14 16
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
[S
pe
ci
es
] (m
M
)
[Decavanadate]total (mM)
 
 
 V1
 V4
 V10
region of the electromagnetic spectrum and the yellow color observed for decavanadate 
solutions is due to an intense absorption tailing in from the ultraviolet [2]. The broad 
absorption band observed for decameric species (Fig. 4A) is well resolved by the 
second derivative of the UV/Vis spectra (Fig. 4B) presenting the shape of two valleys 
with minimum centered at 358 and 400 nm [41]. These two bands are characteristic of 
decameric species as they are lacking in the 2nd derivative spectra of metavanadate 
solutions containing mono-, di- and tetrameric species [40]. Moreover, a linear 
correlation is obtained between the intensity of the two bands and the concentration of 
decavanadate solution (from 0.05 to 2 mM total vanadium) (Fig. 5). Therefore, 
decameric species as low as 5 µM (50 µM total vanadium concentration) can be 
detected by UV/Vis spectroscopy and the dissociation kinetics followed [40]. 
Decavanadate decomposition follows a first order kinetic process, assessed by 
measurements of the absorption band at 400 nm as a function of time, with half-life 
times that are exceedingly dependent on the conditions of the medium including pH, 
temperature, ionic strength, buffer and other assay components. In addition, decameric 
vanadate may become inaccessible to decomposition due to their stabilization upon 
binding to target proteins. An increase of the half-life time from 5 to 17 and 27 hours 
was found in the presence of sarcoplasmic reticulum vesicles and actin, respectively, at 
room temperature and pH 7.0 [42]. This stabilization effect is not extendable to all 
proteins known to interact with decavanadate. For the particular case of myosin, the 
half-life time of decameric vanadate was found to be the same (~158 min) in the 
absence or presence of myosin in a medium containing 25 mM KCl, 25 mM Hepes (pH 
7.0) at 25 ºC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Vanadium (V) species composition of decavanadate solutions upon dilution in a reaction 
medium containing 25 mM KCl, 25 mM Hepes (pH 7.0) at 25 ºC. A series of 51V NMR spectra of the 
decavanadate solutions were recorded at concentrations up to 15 mM (total vanadium concentration). The 
concentration of each vanadium (V) species was calculated from the fractions of the total integrated areas 
observed in the spectra. Notice that V10 shows a linear correlation with the increase in total vanadate 
concentration. 
 
Decameric species is thermodynamically unstable but the lability of this 
oxoanion allows it to be used in studies of limited duration. By selecting the proper 
conditions, it is possible to determine the effects of decameric species in the activity of 
enzymes, at physiological pH and room temperature, provided that the putative effects 
 8 
of the monomeric species are deduced. For this reason, it is desirable to precisely 
characterize the composition and the interaction of the decavanadate solutions with the 
system before attempting to understand the promoted effects. In chapter 9 of this book, 
aspects related with decameric vanadate in vivo effects are being reviewed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. UV/Vis absorption spectra (panel A) and resultant second derivative (panel B) of decavanadate 
(0.05; 0.1; 0.25; 0.5; 1 and 2 mM total vanadium) and metavanadate (2 mM) upon dilution of the 
concentrated stock solutions in 25 mM KCl, 25 mM Hepes (pH 7.0) at 25 ºC. The broad absorption band 
observed for decameric species is well resolved by the second derivative of the UV/Vis spectra presenting 
the shape of two valleys with minimum centered at 358 and 400 nm. 
  
 
 
 
 
 
 
 
 
 
 
5. INHIBITION OF MYOSIN ATPase ACTIVITY AND MODULATION OF 
ACTIN-MYOSIN INTERACTION BY DECAVANADATE 
 
 Among the free or complexed forms of vanadate, decameric species has an 
outstanding potency in a number of systems. Numerous enzymes were shown to be 
inhibited by this oxoanion including several kinases, phosphorylases, the glycolytic 
enzyme aldolase as well as enzymes of inositol phosphate metabolism [reviewed in ref 
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Figure 5. Intensity (arbitrary units) of the 2nd 
derivative bands (shown in Fig. 4B) as a 
function of decavanadate concentration (total 
vanadium concentration). A linear correlation 
is obtained between the intensity of the two 
bands and the concentration of decavanadate 
solution. 
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6,8]. Rabbit skeletal muscle adenylate kinase was the first enzyme reported to be 
inhibited by decavanadate (Ki = 1 µM) [43]. Apparently the susceptibility to V10 is due 
to the tetraphosphate domain over the AMP/ATP binding site on the enzyme. In fact, 
decavanadate is known to bind at the polyphosphate binding sites of enzymes or 
receptors either in the substrate domain or in an allosteric effector site and it does not 
tend to follow a simple competitive model. For example, hexokinase was reported to be 
inhibited (Ki = 62 µM) by decavanadate in a noncompetitive way regarding both ATP 
and glucose [44]. Phosphofructokinase inhibition (Ki = 45 nM) is antagonized by 
positive allosteric effectors and is synergistic with ATP, suggesting that decavanadate 
may interact with both the substrate and effector binding sites [44]. Cyclic AMP-
dependent protein kinase was found to be non-competitively inhibited regarding ATP 
(Ki = 0.8 mM) and competitively inhibited regarding the substrate, kemptide (Ki = 1.4 
mM), by decavanadate [45]. Ribonuclease A inhibition by decavanadate suggests a 
model with more subtlety than a simple competition with poly(C) for the active site 
[46].  
 Further evidence for the interaction of decavanadate at polyphosphate binding 
sites is the inhibition of ATPases although little is known about the mechanism of 
inhibition of this type of enzymes. ATPases hydrolyse phosphate-anhydride bonds and, 
therefore, inhibitory studies assume that vanadate acts as a phosphate analogue 
inhibiting the enzyme as a transition state analogue for the phosphoryl group transfer. 
However, decavanadate is structurally different from orthovanadate and cannot certainly 
mimic orthophosphate in its interaction with enzymes. For example, it has been reported 
that the K channel interacts specifically with decavanadate and not with orthovanadate 
[47]. Binding studies with the sarcoplasmic reticulum Ca2+-ATPase showed that 
whereas orthovanadate is bound to the phosphorylation site, decavanadate interacts with 
the nucleotide site [39]. For the mismatch DNA-binding protein - MutS, inhibition by 
orthovanadate takes place by a similar mechanism to that described for other ATPases 
while decavanadate appears to produce a steric impediment of the protein ATP/ADP 
exchange by interacting with the complex MutS-ADP-Mg [48]. More recently, we have 
recognized a similar pattern of inhibition with respect to the myosin ATPase activity, 
i.e., ortho- and decavanadate appear to act through distinct inhibition mechanisms. 
 Enzymatic kinetic studies indicated that, unlike orthovanadate, decameric 
species is able to strongly inhibit the actin-stimulated ATPase activity of myosin or S1 
with an IC50 in the micromolar range (Fig. 6). These results attested the initial 
hypothesis that the inhibition of the actin-stimulated myosin ATPase activity by 
milimolar vanadate concentrations is, in reality, due to the presence of vanadate 
oligomers and not to the monomeric species. The chance that this inhibition could be a 
result of a direct competition between actin and decavanadate was excluded because the 
increase of actin concentration fixing myosin concentration did not increase the IC50 for 
V10 but at most slightly decrease it, being 20-fold higher in its absence [49]. A more 
detailed kinetic analysis revealed that the inhibition is also non-competitive to ATP 
yielding an inhibition constant (Ki = 0.27 ± 0.05 µM) that is in the range of Ki values 
previously reported for enzymes inhibited by decavanadate (see above). 
The modulation of the actin-myosin interaction by decavanadate was further 
examined using the light-scattering technique [49]. These studies indicated a positive 
correlation between the extent of V10 inhibition of the actomyosin ATPase activity and 
the time needed for the re-association of actin to myosin, after ATP addition. On the 
other hand, decavanadate binding did not dissociate either the ATP-free rigor actin-
myosin complex or the actin-myosin-MgADP complex. In other words, while 
decavanadate does not promote dissociation of myosin from actin, it does prevent its 
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formation until ATP level in the solution is sufficiently low for the re-association 
process to occur. Moreover, fluorescent studies confirmed that the inhibition is the 
result of decavanadate binding to a high affinity site (Kd = 0.16 -0.27 µM) near the 
myosin catalytic centre and that this affinity is modulated by the conformational 
changes that takes place during the catalytic cycle, as indicated by the 2-3 fold increase 
of the dissociation constant produced in the presence of ADP·Vi and ADP·AlF4, which 
induce the conformation of the intermediate metastable state, generated during the 
contractile cycle [49]. Altogether, these results suggested that the inhibition of the actin-
stimulated myosin ATPase activity by decavanadate was the consequence of slowing 
down the catalytic cycle by binding at a regulatory site different from - but near - the 
nucleotide site of the catalytic centre, and likely to be located close to the functional 
protein domains altered upon F-actin filament binding to S1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Inhibition of the actin-stimulated ATPase activity of myosin (circles) or myosin Subfragment-1 
(squares) by vanadate (given as total vanadium concentration). In the presence of actin, decameric 
vanadate, unlike the monomer, is able to inhibit the myosin ATPase activity in the micromolar range. The 
assays were performed using a coupled enzyme system as described elsewhere [49] with 50 µg/ml 
enzyme and 5 µM F-actin, at 25ºC, in a medium containing 10 mM Tris-HCl, pH 7.0, 2.5 mM MgCl2 and 
2 mM ATP. The lines are the nonlinear least squares fit of the data to a Michaelis-Menten-like equation 
with the following parameter values: Imax = 100 and IC50 = 6.11 ±0.74 µM V10 (or 61.1 ±7.4 µM total 
vanadium) and IC50 = 1.36 ±0.14 µM V10 for myosin and S1, respectively [40]. 
 
6. DECAVANADATE AS A PHOTOCLEAVAGE AGENT OF MYOSIN  
 
Unlike phosphate, vanadate is able to induce photolytic cleavage of vanadate-
protein complexes under UV irradiation. The identification of the cleaved polypeptide 
may provide remarkable structural information about vanadate binding sites on enzymes 
extending the use of vanadate as a chemical probe. Dynein [50,51] and myosin [29,52-
58] were the first enzymes shown to be photomodified or photocleaved by irradiation of 
vanadate complexes. Several other enzymes have followed including adenylate kinase 
[59], tubulin [60], aldolase [61], sarcoplasmic reticulum Ca-ATPase [36,37], 
phosphofructokinase [62] or glycogen phosphorylase [63]. Although the vanadate 
mediated photocleavage phenomenon has been reported for at least 10 different 
enzymes, myosin is one of the few systems in which the mechanism of the reactions 
involved are well characterize. This is due in part to the difficulty in sequencing the 
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amino termini resulting from cleavage. The photocleavage of skeletal muscle myosin at 
the active site turned out to be an unusual case as the oxidative steps can be performed 
sequentially and the stable intermediates characterized [64]. Irradiation of the 
myosin·MgADP·Vi complex starts to covalently modify the peptide backbone by 
promoting the oxidation of the hydroxymethyl side chain of Ser-180 to a serine 
aldehyde. This photomodified myosin reforms a new MgADP·Vi complex and upon a 
second irradiation, the myosin heavy chain is specifically cleaved at the active site. A 
key step in this process involves addition of molecular oxygen to a stabilized seryl 
radical generated by a light-catalyzed vanadate reduction to VIV (vanadyl ion). Detailed 
mechanistic studies have found out that the cleaved peptide is in the glicine-rich 
phosphate binding loop (P-loop) homologous to the nucleotide binding site of several 
enzymes including ATP-binding cassette (ABC) transporters or other ATPases. This 
sequence has the general formula G-X1-X2-X3-X4-G-K-G/T in which X2 corresponds to 
the aminoacid cleaved: for example, an alanine in dynein and β-ATP synthase, a proline 
in adenylate kinase, an arginine in α-ATP synthase and a serine in the particular case of 
myosin [50,53,54,59,65]. Curiously, the cleavage is determined by the location of the 
aminoacid and not by its nature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the absence of bound nucleotides, vanadate was found to be able to cleave the 
myosin heavy chain (95 kDa) only when the concentration was above 0.2 mM [29]. 
Since 51V NMR studies had shown before that tetrameric vanadate binds most strongly 
to myosin and is known to be present at vanadate concentrations higher than 0.2 mM, 
this species was suggested to be responsible for the photocleavage reaction. In the 
presence of 0.2 mM vanadate concentration, the extent of cleavage was small occurring 
in two distinct sites located at 23 and 31 kDa from the N-teminal. With the increase of 
vanadate concentration, the extent of cleavage increased and an additional product with 
74 kDa appeared in the electrophoretic pattern. While the presence of ATP specifically 
inhibits the vanadate-associated cleavage of myosin heavy chain at the 23 and 31 kDa 
sites, actin specifically inhibits the cleavage at the 74 kDa site [29,58]. The exact 
positions of the 23 and 31 kDa cleavage sites were assigned to Ser-180 [53] and Ser-243 
[64] respectively, both located on highly conserved regions at the myosin active site of 
rabbit skeletal muscle myosin.  According to the X-ray structure of the truncated head 
of Dictyostelium myosin complexed with MgADP, the side chains of the analogues of 
Figure 7.  Ribbon representation of 
the γ-phosphate pocket of the 
truncated head of Dictyostelium 
myosin complexed with MgADP·VO4. 
Protein coordinates were taken from 
PDB with the accession number 
1VOM [66]. The heavy chain is 
displayed in green except the 
conserved motives forming the Pi-tube 
which are colored in red, magenta and 
cyan for the P-loop, switch I and 
switch II domains, respectively. 
MgADP, VO4, Ser-181 and Ser-236 
are depicted in gray, yellow, red and 
magenta, respectively, as stick 
representation.  Note that both Ser-181 
and Ser-236 are in position to form 
hydrogen bonds with the oxygens of 
the vanadate molecule.  
Ser-181 
Ser-236 
VO4 
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these two residues (Ser-181 and Ser-236) form hydrogen bonds with the oxygens of the 
vanadate molecule (Fig. 7) [66]. The aminoacids involved in the third cleavage site (74 
kDa), although not yet identified were demonstrated to be placed at the 50/20 kDa 
proteolitic fragments junction where the Loop-2 (residues 627-646 of rabbit skeletal 
muscle myosin) is encountered. This lysine-rich polyphosphate binding site was proved 
to participate in the myosin-actin interaction. 
More recently, it has been demonstrated that besides monomeric and tetrameric 
vanadates, also the decamer is photoactive being rapidly decomposed, through the 
photoreduction of vanadate atoms to vanadyl, during the photocleavage process (Fig. 8). 
While for decavanadate cleavage initiates at vanadate concentrations as low as 5 µM (~ 
0.5 µM V10 species), for metavanadate cleavage is almost negligible at concentrations 
lower than 100 µM and only above 200 µM (when tetrameric species start to appear) 
the extent of cleavage is comparable to the decavanadate-promoted photocleavage [32]. 
Additionally, the identical cleavage patterns found for meta- and decavanadate solutions 
in the absence or presence of the myosin natural ligands, ATP and actin [32], suggest 
that V4 and V10 share the same myosin binding sites (in agreement with previous NMR 
studies), namely one of higher affinity (23 kDa) at the consensus ATP binding site and 
another one of lower affinity (74 kDa) at the actin-binding interface.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Vanadate-dependent cleavage of myosin Subfragment-1 (4.5 µM) upon UV irradiation in a 
medium containing 25 mM KCl, 2.5 mM MgCl2, 25 mM Hepes (pH 7.0) at 25 ºC. A: Development of the 
74 kDa cleavage product upon increasing vanadate concentration [32]. B: The products of decavanadate 
reduction in the presence of myosin subfragment-1 and actin give rise to EPR signals typical of vanadyl 
(VIV) ions [40].  
 
7. VANADIUM(V) AS A POWERFUL TOOL IN THE ELUCIDATION OF 
MYOSIN ATPASE ACTIVITY 
 
The ability to visualize a transition state analogue is a powerful tool for 
understanding the dynamics of enzyme mechanisms as they can help mapping the 
enzyme active site and reveal conformational changes that may take place in the course 
of the catalytic cycle. The vanadate ion (VO43-) is able to act as an analogue for the 
conformation of the phosphate group at the transition state expected for phosphoryl 
transfer or hydrolysis, in part because it has very similar size and charge to inorganic 
phosphate, but also because it tends to adopt pentacoordinate complexes exhibiting 
trigonal bipyramidal geometry [67]. In the myosin·MgADP·VO4 complex, vanadate 
exhibits this geometry forming one apical bond to the β-phosphate of ADP but with no 
covalent linkages to the enzyme (see Fig. 7). This structure is a realistic analogue of the 
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metaphosphate-like transition state for phosphoryl transfer [66,68]. Vanadate is 
frequently replaced by aluminium and berilium fluoride as phosphate analogues on 
account of vanadate tendency to polymerize and due to its photoreactivity. Although the 
ions AlF4- and BeF3- approximate the shape and charge of phosphate, they do not 
function as true analogues of the transition state for phosphate ester bond cleavage [66-
68]. While beryllium fluoride moiety in the myosin active site is tetrahedral, 
representing the ground state prior hydrolysis, aluminium fluoride is approximately 
square bipyramidal [69]. The X-ray resolution of the MgADP·VO4 structure in the 
catalytic domain of myosin Dictyostelium disciudeum (S1dC) revealed how the protein 
ligands and water structure surrounding the γ-phosphate pocket were oriented to 
stabilize a water molecule in an appropriate position for in-line nucleophilic attack on 
the γ-phosphorus of ATP [66]. Besides providing insights into the structural basis of 
ATP hydrolysis, the ADP·vanadate structure has also captured a key conformational 
change playing an important role in the generation of movement. It has been observed 
that in the structure of the ADP·vanadate complex there is reduce access of the solvent 
to the γ-phosphate pocket. This is caused by a closure of the Pi-tube located at the apex 
of a large cleft that divides the 50 kDa fragment into upper and lower domains at the 
rear opening of the active site [66]. However, in the structure of the S1dC complexed 
with MgADP·BeF or MgATP the γ-phosphate is partially visible because there is a clear 
opening of the Pi-tube into the large 50 kDa cleft [69]. The former conformational 
change has been suggested to be required for hydrolysis and attainment of the ADP·Pi 
state meaning that the phosphate group will be trapped in the Pi-tube until a second 
conformational rearrangement occurs by the rebinding of myosin to actin [70]. It is thus 
comprehensible that considerable biochemical and biophysical effort has been expended 
on the S1·MgADP·VO4 complex as part of the greater goal of understanding the 
molecular basis of muscle contraction. 
Apparently, decavanadate cluster is too large to form an enzyme-vanadate 
complex capable of providing insight into phosphoryl transfer reactions. Nevertheless, 
if decavanadate is able to trap the contractile cycle at a critical point, that is necessarily 
different from the one trapped by orthovanadate, then, it could provide a good 
opportunity to further comprehend the modulation of the actin-myosin interaction. 
Indeed, based on molecular docking simulations of the oligomer on three different 
structures of the myosin motor domain of Dictyostelium discoideum representing 
distinct states of the ATPase cycle, decavanadate was suggested to prevent a crucial 
conformational change for the hydrolysis of the ATP-γ-phosphate [71]. The theoretical 
results indicated a clear preference of V10 to bind at the rear opening of the Pi-tube (the 
so called “back-door” [72,73]) but only on the “open” structures where there is access to 
the phosphate binding-loop (P-loop) such as the free or the ATP-bound conformations. 
As expected, in the S1dC·MgADP·VO4 X-ray structure, the back-door does not 
represent an energetically favourable solution since the 50 kDa cleft is closed blocking 
the Pi-tube and concomitantly the access of decavanadate to the P-loop. The proposed 
binding location explains how the 10 Å decavanadate molecule gains access to Ser-181, 
a residue located on the P-loop, previously shown to be cleaved upon irradiation in the 
presence of the oligomer, without having to squeeze through the narrow entrance of the 
Pi-tube at the nucleotide binding site. Furthermore, it provides a simple mechanism for 
the experimentally observed non-competitive inhibition pattern of V10 towards both 
ATP and actin as it does not interfere with the nucleotide binding site or the actin 
binding surface.  
The enzymes inhibited by decavanadate appear to be all prearranged to bind 
phosphoryl groups, but decavanadate inhibition is by no means a general property of all 
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such enzymes and, therefore, the structural and conformational characteristics of the 
enzymes are certainly important. For instance, the walker A motive (corresponding to 
the P-loop in myosin) of ABC ATPases has been shown to be a highly adapted anion-
binding domain that can bind decavanadate with high affinity [48]. Unlike 
orthovanadate, decavanadate appears to interact outside the walker A loop but needs to 
be stabilized by certain residues nearby. As a result, only some members of the ABC 
superfamily are able to interact with the oligomer. In what concerns myosin, the specific 
phosphate-binding domains in the vicinity of the back-door provide electrostatic 
interactions which favor an approach of this polyanionic species to the rear opening of 
the Pi-tube (Fig. 9). Once “accommodated” to the 50 kDa cleft and stabilized by certain 
residues nearby, the large size of decavanadate is likely to interfere with movements 
associated with closure of the cleft, a critical conformational change necessary to carry 
out the ATP-γ-phosphate hydrolysis. Therefore, by forming the intermediate 
myosin·MgATP·V10 complex, decavanadate will act as a “back-door” stop blocking the 
actomyosin cycle, most likely, in the pre-hydrolysis state.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. CONCLUDING REMARKS 
 
Interest in the interaction of vanadium oxoanions with biological systems has 
increased gradually since it was demonstrated to have a variety of physiological effects, 
acting either as a phosphate analogue in the monomeric form (H2VO4-) or through 
oligomeric vanadate species. In muscles, where it was rediscovered for biological 
studies, several enzymes are inhibited by this oxoanion, namely myosin, a highly 
specialized protein which along with actin is able to convert the chemical energy of 
ATP hydrolysis into mechanical movement. Monomeric vanadate affects the ATPase 
activity of myosin through the formation of a complex with MgADP that mimics the 
conformation of the myosin head in the transition state for ATP hydrolysis. As would be 
expected for such a transition state mimic, vanadate has been widely used as a very 
useful tool to elucidate myosin catalytic mechanisms and substrate binding modes. 
Although the mechanism of inhibition of the monomeric species towards myosin has 
been relatively well characterized, very little has been described about the contribution 
ATP 
V10 
Figure 9. Map of the surface 
electrostatic potential of myosin 
subfragment-1, with the resulting 
docked conformation of 
decavanadate (red spheres) on the 
“back-door” region. The ATP 
molecule depicted in green has been 
introduced to show the location of 
the active site with respect to the 
decavanadate molecule. Positive, 
neutral and negative surface 
potential are coloured in red, white 
and blue, respectively. Note how the 
decavanadate molecule with an 
ellipsoidal shape is perfectly 
adjusted to the 50 kDa cleft at the 
rear of the nucleotide site.   
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of vanadate oligomers in the biochemical/structural properties of myosin. The latter 
point is of relevance since it could provide structural/functional tools for further 
understanding the mechanism of myosin action and it could address one of the most 
interesting questions of the field: the role of vanadate in the in vivo regulation of myosin 
and other molecular motors. 
Very often studies describing interactions of vanadate with proteins consider 
only monomeric vanadate as the active species, disregarding the possible contribution 
of other vanadate oligomers which are favoured at higher vanadate concentrations or 
through a slight acidification of the medium. In the present review we become aware of 
the fact that observation of inhibition of an enzyme system cannot be taken as evidence 
that monomeric vanadate is the inhibiting species and that individual vanadate species 
can differently affect an enzyme mechanism. In what concerns myosin, vanadate is able 
to populate different conformational states of the myosin ATPase cycle depending on its 
oligomerization state. While monomeric vanadate (VO43-) mimics the transition state for 
the γ-phosphate hydrolysis blocking myosin in a pre-power-stroke state, decameric 
vanadate (V10O286-) induces the formation of the intermediate myosin·MgATP·V10 
complex blocking the contractile cycle presumably in the pre-hydrolysis state. The 
former complex is destabilized in the presence of actin, comparable to the in vivo 
conditions, whereas the latter is not. Therefore, the mode of action of vanadate on the 
inhibition of the actomyosin ATPase activity depends, at least in part, on the charge and 
size of the vanadate species, being favoured for those with higher oligomerization state, 
such as the decameric species.  
Unlike the simple and labile vanadate oligomers including the monomer (V1), 
dimer (V2), tetramer (V4) and pentamer (V5), which interchange with each other on the 
millisecond to second time scale in neutral and alkaline aqueous solutions, decavanadate 
interconversion with the other vanadate oligomers occurs on a considerably longer time 
scale. Moreover, even though at physiological pH decavanadate is not the most 
thermodynamically stable, hydrolysis into other vanadate oligomers is very slow and 
therefore it is sufficiently long lived so its effects can be determined in the biological 
systems under study. This constitutes a great advantage in regard to the other vanadate 
oligomers in which the effects of each species must be examined in an equilibrium 
mixture and correlated with changes in the concentration of the different vanadate ions. 
In addition to its lower lability, the physicochemical properties of decavanadate allows 
it to be analysed through several techniques including 51V NMR and UV-Vis 
spectroscopy, as well as to be used as a probe through photolytic cleavage reactions. 
Regardless of the controversy around the possibility of existence of the decameric 
species at physiological conditions, which is out of the scope of this review, 
decavanadate remains as an excellent biochemical tool in such important aspects as: 1) 
to gain a deeper knowledge about the modulation of actin-myosin interactions in the 
process of muscle contraction; 2) to the description of the location and function of the 
phosphate binding sites on myosin; 3) to further understand the basic structural 
requirements for high affinity protein binding sites to decavanadate;  and 4) to a more 
general knowledge about polyanion-enzyme interaction.  
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